Galderma CEO anticipates continued high growth rates

Galderma CEO Flemming Ørnskov anticipates continued high revenue growth for the skincare company, driven primarily by product innovation. The company is set to join the Swiss Market Index (SMI) next week, a milestone Ørnskov noted occurred only two and a half years after the company's IPO.

Growth has been supported by expansion into new markets, including China, India, Latin America, and the United States. The company is now focused on introducing its extensive product portfolio to these regions, with strong performance noted for products such as the skin medication Nemluvio and the biostimulator Sculptra.

Regarding regulatory matters, Ørnskov expressed confidence regarding the wrinkle treatment Relfydess following requests for improvements from US authorities. A meeting with the FDA is expected in the coming months to address specific points. Additionally, the CEO indicated a cautious approach to acquisitions, seeking complementary additions in the aesthetics or consumer goods sectors rather than focusing solely on scale.